PMID- 32021356
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220412
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 13
DP  - 2020
TI  - Serum Ferritin Independently Predicts the Incidence of Chronic Kidney Disease in 
      Patients with Type 2 Diabetes Mellitus.
PG  - 99-105
LID - 10.2147/DMSO.S228335 [doi]
AB  - AIM: This study aimed to determine whether serum ferritin (SF) is an independent 
      risk factor of the incidence of chronic kidney disease (CKD) and rapid renal 
      function decline (RFD) in male Tibetan patients with type 2 diabetes mellitus 
      (T2DM). METHODS: We performed a retrospective cohort study that included 191 male 
      Tibetan patients with T2DM without CKD. Patients were divided into three groups 
      according to the level of SF. The following outcomes were measured: cumulative 
      incidence of chronic kidney disease [i.e. estimated glomerular filtration rate 
      (eGFR) <60 mL/min per 1.73 m(2) and/or urinary albumin/creatine ratio (ACR) >/=30 
      mg/g] and RFD (i.e. decrease in eGFR of >/=25% from baseline or a decline rate of 
      >/=3 mL/min per 1.73 m(2) annually). RESULTS: In total, over a median follow-up 
      period of 23 months, 30 (15.7%) and 89 patients (46.6%) developed CKD and RFD. In 
      multivariable Cox models, a 100 ng/mL increment in SF was associated with a 
      1.12-fold (95% CI: 1.02-1.24) higher adjusted risk for incidence of CKD. The 
      adjusted-HR of CKD was 1.31 (95% CI: 0.38-4.53) and 2.92 (95% CI: 0.87-9.77) for 
      those in tertile 2 and tertile 3, respectively, compared with the patients in 
      tertile 1. However, SF was not significantly associated with RFD (adjusted-HR: 
      1.06, 95% CI: 0.99-1.14). CONCLUSION: Serum ferritin independently predicts the 
      incidence of CKD in male Tibetan patients with T2DM. High levels of serum 
      ferritin may play a role in the pathogenesis leading to the development of CKD in 
      T2DM.
CI  - (c) 2020 Wu et al.
FAU - Wu, Yun Hong
AU  - Wu YH
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Wang, Su Yuan
AU  - Wang SY
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Li, Ming Xia
AU  - Li MX
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - He, Hua
AU  - He H
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Yin, Wei Jin
AU  - Yin WJ
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Guo, Yan Hong
AU  - Guo YH
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Zhang, Hui Qin
AU  - Zhang HQ
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Sun, Zeng Mei
AU  - Sun ZM
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Zhang, Dan
AU  - Zhang D
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Wang, Xi
AU  - Wang X
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Sun, Shu Yao
AU  - Sun SY
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Tang, Shu Xi
AU  - Tang SX
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Du, Rong
AU  - Du R
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
FAU - Zhang, Cheng Hui
AU  - Zhang CH
AD  - Department of Endocrinology and Metabolism, Hospital of Chengdu Office of 
      People's Government of Tibetan Autonomous Region, Chengdu, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200114
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC6970239
OTO - NOTNLM
OT  - chronic kidney disease
OT  - serum ferritin
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/02/06 06:00
MHDA- 2020/02/06 06:01
PMCR- 2020/01/14
CRDT- 2020/02/06 06:00
PHST- 2019/08/22 00:00 [received]
PHST- 2019/11/29 00:00 [accepted]
PHST- 2020/02/06 06:00 [entrez]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/02/06 06:01 [medline]
PHST- 2020/01/14 00:00 [pmc-release]
AID - 228335 [pii]
AID - 10.2147/DMSO.S228335 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2020 Jan 14;13:99-105. doi: 10.2147/DMSO.S228335. 
      eCollection 2020.